Interpace Biosciences (OTCMKTS:IDXG) Shares Pass Above 200-Day Moving Average – What’s Next?

Interpace Biosciences, Inc. (OTCMKTS:IDXG) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.65 and traded as high as $1.71. Interpace Biosciences shares last traded at $1.57, with a volume of 12,108 shares traded.

Interpace Biosciences Stock Performance

The company has a 50 day simple moving average of $1.89 and a two-hundred day simple moving average of $1.66. The firm has a market cap of $7.38 million, a PE ratio of -33.34 and a beta of 0.59.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.The firm had revenue of $9.03 million during the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.